Literature DB >> 2112071

Thyroid function in patients with myotonic dystrophy.

H Fukazawa1, T Sakurada, K Yoshida, N Kaise, K Kaise, T Nomura, M Yamamoto, S Saito, S Takase, K Yoshinaga.   

Abstract

In order to investigate endocrine disturbances in patients with myotonic dystrophy (MD), 12 patients and 20 normal controls were studied. All patients were clinically euthyroid and there were no significant differences between circulating levels (mean +/- SD) of T4 (114.7 +/- 26.8 vs 129.9 +/- 28.3 nmol/l), FT4 (16.6 +/- 4.5 vs 18.4 +/- 3.8 pmol/l), T3 (1.61 +/- 0.29 vs 1.86 +/- 0.33 pmol/l), TSH (2.7 +/- 1.3 vs 2.4 +/- 1.4 mU/l), TBG (26.7 +/- 5.5 vs 27.6 +/- 4.9 mg/l), T4/T3 (84.3 +/- 18.4 vs 82.1 +/- 15.3), and FT4/FT3 (0.28 +/- 0.05 vs 0.33 +/- 0.08). Serum FT3 (4.3 +/- 1.4 pmol/l) in patients were significantly lower than those (5.3 +/- 0.9 pmol/l) in normal controls (P less than 0.02). Thyroidal 131I-uptakes (8.7 +/- 4.3%) in patients were significantly lower than those (25.8 +/- 7.4%) in controls (P less than 0.01). The mean maximal TSH responses following TRH stimulation were significantly less in patients with MD (11.4 +/- 4.5 vs 17.0 +/- 6.2 mU/l; P less than 0.02). Neither circulating thyroid microsomal nor thyroglobulin antibodies were detectable in the 11 patients tested. Serum thyroglobulin concentrations were within the normal range in all patients but one. In conclusion, it is suggested that normal levels of serum T4, T3, FT4, TSH, TBG, T4/T3 and FT4/FT3, slight but significant decrease of serum FT3, reduced TSH response to TRH and a decrease of thyroidal radioiodine uptake might be due to a slight functional failure of TSH secretion in patients with myotonic dystrophy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112071     DOI: 10.1111/j.1365-2265.1990.tb00889.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Endocrine function in 97 patients with myotonic dystrophy type 1.

Authors:  M C Ørngreen; P Arlien-Søborg; M Duno; J M Hertz; J Vissing
Journal:  J Neurol       Date:  2012-02-17       Impact factor: 4.849

2.  Increased cancer risks in myotonic dystrophy.

Authors:  Aung Ko Win; Promilla G Perattur; Jose S Pulido; Christine M Pulido; Noralane M Lindor
Journal:  Mayo Clin Proc       Date:  2012-01-10       Impact factor: 7.616

3.  High CTG repeat number in nodular thyroid tissue from a myotonic dystrophy patient.

Authors:  C Daumerie; N Lannoy; J P Squifflet; G Verellen; C Verellen-Dumoulin
Journal:  J Med Genet       Date:  1994-11       Impact factor: 6.318

4.  Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1.

Authors:  Luc Laberge; Benjamin Gallais; Julie Auclair; Yves Dauvilliers; Jean Mathieu; Cynthia Gagnon
Journal:  J Neurol       Date:  2019-10-31       Impact factor: 4.849

5.  Primary Hyperparathyroidism and Hyperthyroidism in a Patient with Myotonic Dystrophy: A Case Report and Review of the Literature.

Authors:  Yosra Cherif; Baha Zantour; Wafa Alaya; Olfa Berriche; Samia Younes; Mohamed Habib Sfar
Journal:  Case Rep Endocrinol       Date:  2015-06-15

6.  Thyroid Hormones Play Role in Sarcopenia and Myopathies.

Authors:  Flavia F Bloise; Thamires S Oliveira; Aline Cordeiro; Tania M Ortiga-Carvalho
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.